Azzazy Hassan M E, Christenson Robert H
Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
Clin Biochem. 2002 Feb;35(1):13-27. doi: 10.1016/s0009-9120(02)00277-1.
Major challenges for physicians include selection of effective tests in the time-sensitive identification and management of patients with acute coronary syndromes (ACS). We review whether cardiac marker testing performed at the point-of-care (POC) has an impact on clinical management and guidance of intervention for ACS patients.
Evidence from recently published studies and meta-analyses supports the efficacy of cardiac markers. Technologies and specifications of all currently available POC tests for monitoring cardiac markers are surveyed. Finally, a series of questions to investigate the utility of cardiac markers, and their measurement by POC tests, for clinical management and guidance of therapy for ACS patients, are addressed.
Cardiac troponins are clearly the best markers for the definitive detection of myocardial infarction. Compelling evidence for the utility of troponins in risk stratification and guidance of intervention for ACS patients has resulted in inclusion of cardiac markers in clinical guidelines. Rapid multi-analyte POC tests, few of which exhibit harmony with central laboratory assays, have facilitated the use of cardiac markers for clinical management and guidance of therapy.
Given the need to minimize vein-to-brain time, it is expected that point-of-care testing of cardiac markers will take a leading role in management of ACS patients.
对于医生而言,主要挑战包括在对急性冠状动脉综合征(ACS)患者进行时间敏感型识别和管理时选择有效的检测方法。我们回顾了即时检测(POC)心脏标志物是否会对ACS患者的临床管理和干预指导产生影响。
近期发表的研究和荟萃分析的证据支持了心脏标志物的有效性。对目前所有用于监测心脏标志物的即时检测技术和规格进行了调查。最后,提出了一系列问题,以探讨心脏标志物及其通过即时检测进行测量在ACS患者临床管理和治疗指导中的效用。
心肌肌钙蛋白显然是确诊心肌梗死的最佳标志物。肌钙蛋白在ACS患者风险分层和干预指导中的效用有令人信服的证据,这使得心脏标志物被纳入临床指南。快速多分析物即时检测,其中很少与中心实验室检测结果一致,这促进了心脏标志物在临床管理和治疗指导中的应用。
鉴于需要尽量缩短静脉到脑的时间,预计心脏标志物的即时检测将在ACS患者的管理中发挥主导作用。